A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/01/2011	WO2011100642A3 Method for treating hematological cancers
12/01/2011	WO2011097522A3 Combination methods for treatment of disease
12/01/2011	WO2011094260A3 Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
12/01/2011	WO2011093524A9 Di - substituted pyridine derivatives as anticancers
12/01/2011	WO2011091213A3 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
12/01/2011	WO2011090316A3 Novel pyrazinone derivatives having an apoptosis-inducing activity, and pharmaceutical compositions comprising same
12/01/2011	WO2011090283A3 Composition containing inhibitors of the expression or activity of sh3rf2 for preventing or treating cancer
12/01/2011	WO2011087343A3 Composition for treating cancer related to an hpv infection
12/01/2011	WO2011087299A3 Pharmaceutical composition for the treatment of cancer, containing an extracellular matrix of mesenchymal stem cells derived from umbilical cord blood as an active ingredient
12/01/2011	WO2011086143A3 Liver targeting domain antibodies
12/01/2011	WO2011081443A3 Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof
12/01/2011	WO2011081415A3 Sirna for inhibiting c-met expression and an anti-cancer composition comprising the same
12/01/2011	WO2011063336A3 Secondary site of antigen stimulation for therapeutic vaccination
12/01/2011	US20110296544 Colon cancer targets and uses thereof
12/01/2011	US20110296538 In vivo quantitative screening test for anti-metastasis treatment efficacy
12/01/2011	US20110295225 Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
12/01/2011	US20110294984 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
12/01/2011	US20110294902 Pharmaceutical compositions providing enhanced drug concentrations
12/01/2011	US20110294900 Self emulsifying drug delivery system for a curcuminoid based composition
12/01/2011	US20110294895 Bis(thio-hydrazide amide) formulation
12/01/2011	US20110294892 Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes
12/01/2011	US20110294883 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
12/01/2011	US20110294878 Inhibitors of Dimethylarginine Dimethylaminohydrolase
12/01/2011	US20110294877 Transition metal complexes of bis[thiohydrazide amide] compounds
12/01/2011	US20110294870 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
12/01/2011	US20110294867 Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
12/01/2011	US20110294859 Substituted pyridoxine-lactam carboxylate salts
12/01/2011	US20110294857 Inhibitor of casein kinase 1delta and casein kinase 1epsilon
12/01/2011	US20110294854 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
12/01/2011	US20110294849 Aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
12/01/2011	US20110294846 Indole derivatives as anticancer agents
12/01/2011	US20110294845 Parenteral formulations
12/01/2011	US20110294844 9-aminonoscapine and its use in treating cancers, including drug-resistant cancers
12/01/2011	US20110294838 Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
12/01/2011	US20110294837 Aurora Kinase Modulators and Methods of Use
12/01/2011	US20110294831 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
12/01/2011	US20110294827 Iap binding compounds
12/01/2011	US20110294826 Pyrrolo[2,3-d]pyrimidine compounds
12/01/2011	US20110294820 N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives
12/01/2011	US20110294816 Pyrrolotriazine kinase inhibitors
12/01/2011	US20110294815 Prostacyclin analogs
12/01/2011	US20110294814 Compounds for treating proliferative disorders
12/01/2011	US20110294812 P38 map kinase inhibitors
12/01/2011	US20110294811 Abt-263 crystalline forms
12/01/2011	US20110294806 Azaindole derivatives as kinase inhibitors
12/01/2011	US20110294805 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof
12/01/2011	US20110294802 Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
12/01/2011	US20110294801 Macrocyclics pyrimidines as aurora kinase inhibitors
12/01/2011	US20110294797 Reverse-turn mimetics and method relating thereto
12/01/2011	US20110294796 Benzotriazine inhibitors of kinases
12/01/2011	US20110294795 Methods of synthesis and/or purification of diaminophenothiazinium compounds
12/01/2011	US20110294794 Treatment of proteinopathies using a farnesyl transferase inhibitor
12/01/2011	US20110294793 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors
12/01/2011	US20110294791 Pirenzepine as an agent in cancer treatment
12/01/2011	US20110294790 Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
12/01/2011	US20110294780 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
12/01/2011	US20110294776 Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases
12/01/2011	US20110294772 Use of cyclosquaramide compounds as anti-tumour agents
12/01/2011	US20110294764 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3
12/01/2011	US20110294755 Binding of galectin-3 by low molecular weight pectin
12/01/2011	US20110294754 Novel pharmaceutical compounds
12/01/2011	US20110294752 Triterpene compositions and methods for use thereof
12/01/2011	US20110294746 Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
12/01/2011	US20110294738 Pthr1 receptor compounds
12/01/2011	US20110294727 Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
12/01/2011	US20110294720 Apratoxin therapeutic agents: mechanism and methods of treatment
12/01/2011	US20110294717 Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
12/01/2011	US20110294665 Bioactive agent, pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent
12/01/2011	US20110294146 Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases
12/01/2011	US20110293757 Compositions Comprising Tea Tree Oil and Methods for the Prevention and Treatment of Cancer
12/01/2011	US20110293756 Preventives or remedies for tumor or human papillomaviral disease
12/01/2011	US20110293754 Anticancer composition containing herbal extract
12/01/2011	US20110293753 Tocotrienol Compositions
12/01/2011	US20110293752 Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with Extracts of Noni Juice (Morinda Citrifolia)
12/01/2011	US20110293746 Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders
12/01/2011	US20110293745 Aurora kinase inhibitors
12/01/2011	US20110293744 Benzoxazole inhibitors of poly(adp-ribose)polymerase
12/01/2011	US20110293733 Self-assembling nanoparticle drug delivery system
12/01/2011	US20110293730 Polylactide nanoparticles
12/01/2011	US20110293728 Photosensitizer-metal nanoparticle complex and composition containing the complex for photodynamic therapy or diagnosis
12/01/2011	US20110293727 Chimeric therapeutics, compositions, and methods for using same
12/01/2011	US20110293726 Chimeric therapeutics, compositions, and methods for using same
12/01/2011	US20110293725 Chimeric therapeutics, compositions, and methods for using same
12/01/2011	US20110293723 Synthetic nanocarrier combination vaccines
12/01/2011	US20110293722 Hydrogel sponges, methods of producing them and uses thereof
12/01/2011	US20110293715 Pharmaceutical Formulation and Process for Its Preparation
12/01/2011	US20110293706 Nanoshells on polymers
12/01/2011	US20110293705 Methods and compositions for localized agent delivery
12/01/2011	US20110293701 Multivalent synthetic nanocarrier vaccines
12/01/2011	US20110293700 Nanocarrier compositions with uncoupled adjuvant
12/01/2011	US20110293699 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293698 Reagents and Methods for Treating Cancer
12/01/2011	US20110293695 Amphoteric liposomes
12/01/2011	US20110293691 Multimodal adhesion barrier
12/01/2011	US20110293688 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293672 Pancreatic tumour treatment
12/01/2011	US20110293658 Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
12/01/2011	US20110293656 Recombinant mva capable of expressing structural hcv antigens
12/01/2011	US20110293649 In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles
12/01/2011	US20110293648 Ssx-2 peptides presented by hla class ii molecules

1 ... 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 ... 2211